

Molson Coors

Price USD103.02

New savings targets in line with expectations

Fair Value USD112 vs. USD110 (+9%)

BUY

Bloomberg	TAP US
Reuters	TAP.N
12-month High / Low (USD)	111.3 / 83.6
Market Cap (USDm)	22,136
Ev (BG Estimates) (USDm)	16,081
Avg. 6m daily volume (000)	1,934
3y EPS CAGR	16.7%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-5.2%	3.4%	4.8%	9.7%
Food & Bev.	-7.9%	-7.3%	-2.6%	-7.4%
DJ Stoxx 600	-3.4%	-1.2%	-1.2%	-9.4%

YEnd Dec. (USDm)	2015	2016e	2017e	2018e
Sales	3,568	3,352	11,556	11,759
% change		-6.0%	NM	1.8%
EBITDA	651	634	2,565	2,717
EBIT	352.2	331.5	1,910	2,062
% change		-5.9%	NM	8.0%
Net income	700.4	648.7	1,177	1,292
% change		-7.4%	81.4%	9.8%

	2015	2016e	2017e	2018e
Operating margin	9.9	9.9	16.5	17.5
Net margin	19.6	19.4	10.2	11.0
ROE	9.9	6.6	10.8	10.8
ROCE	2.7	2.5	8.9	7.1
Gearing	38.3	-1.8	90.2	72.0

(USD)	2015	2016e	2017e	2018e
EPS	3.76	3.00	5.44	5.97
% change		-20.2%	81.4%	9.8%
P/E	27.4x	34.4x	18.9x	17.2x
FCF yield (%)	2.1%	3.3%	6.2%	6.7%
Dividends (USD)	1.64	1.64	1.80	1.98
Div yield (%)	1.6%	1.6%	1.8%	1.9%
EV/Sales	5.5x	4.8x	2.8x	2.6x
EV/EBITDA	30.3x	25.3x	12.5x	11.3x
EV/EBIT	55.9x	48.5x	16.7x	14.9x

Q3 results showed that the trading environment in Canada is not getting easier, but that the US business is gaining traction. The newly published all-in efficiency target of USD550m is in line with what we were expecting (USD600 over 3 to 4 years), but most of that will be reinvested to make sure the company does reach its target for flat US volumes in 2018 and growing in 2019.

Last week, Molson Coors reported results after Q3. YTD worldwide beer volumes declined 1.4%, net revenue was down 0.1% in constant currency (a reported 4.9% decline) and underlying EBITDA fell by 0.8%. Following these figures we have updated our model and lowered our forecasts for Canada and to a lesser extent for the European segment. However, we have increased forecasts for the MillerCoors business. Overall we lowered our EPS forecast for 2016 by 8% to USD3.00 from USD3.28 but left 2017 unchanged (rather by accident as the improved US performance compensates the worse than expected Canadian and European business).

ANALYSIS

- All-in efficiency target of USD550m in line with expectations:** In the Q3 2016 release, Molson Coors also updates investors on expected cost savings and synergies after the MillerCoors transaction. It now expects to improve efficiency by USD550m over the next three years (all-in target but it comments that half is cost savings and half synergies). This is very much in line with our previous forecast of USD600 over three/four years and its previous guidance of USD80m in cost savings p.a. for at least two years and USD200m synergies over four years, (which adds up to about USD520m over four years assuming that the costs savings continued), although the delivery is probably on the faster side. But of course there is no hint on how the efficiency improvement is going to be reinvested or flow through to the bottom line. In the past only about 1/3 of Molson Coors's savings went through the bottom line. We assume this will repeat itself and look for about two percentage points operating margin improvement over the next three years. Indeed, with the company continue to target flat volumes in the US by 2018 and growth by 2019, it will have to crank up investments behind its brands.
- Irritated management:** During the call on the results, one participant asked CEO Mark Hunter what his track record is, and why investors should be comfortable that the right management team is on board to execute the significant plans. Answer: "I'm not going to conduct a performance review over our quarterly earnings call or get into detail as to why our board believes that I am the right leader for this business and why I believe Gavin is the right leader for this business." Nevertheless the question is timely: both Mark Hunter and Gavin Hattersley have been around in the group for a long time and today, the company is still only making the same operating profit than years ago (adjusted operating profit incl. MillerCoors of USD869 in 2015 v USD886 in 2010). Mark Hunter has been at Molson Coors since 1989 and has worked his way up first in the European division then in Canada and Asia before becoming CEO of Molson Coors on 1st January 2015. Indeed, on the face of it there does not seem to be much of a track record in moving topline or cutting costs. Gavin Hattersley started at SABMiller in 1998 in South Africa before moving to Miller in 2002 and since 2008 at MillerCoors (via Molson Coors back to MillerCoors in 2015). Also, here there is not the obvious track record in creating value for shareholders. However, Gavin's role in the past has been very much restricted to a pure finance role, whereas, according to insiders, his interest covers both finance and commercial (and in the past with two different shareholders at MillerCoors each having their own agenda and competing in Europe, there were many issues to take into account). But one thing that has coloured Gavin is his resolve to get on with things. On his second day in the job he replaced MillerCoors's chief marketing officer England (with Kroll) and the sales chief McBrien (with Doyle). Nevertheless, however we look at it, the jury is still out for both Mark and Gavin.
- Saved by Cocaine?:** Canada's government has plans to decriminalise and regulate recreational marijuana in spring 2017. Although recreational drugs and alcohol might seem in competition, the experience of Colorado and Washington, is that liberalisation of drug use does improve alcohol consumption (and tourism!). Maybe that is exactly what the Canadian beer industry needs.
- Although the company is trying to put a brave face on it, Molson Coors is having a tough time in Canada and Europe.** In Canada, declining volumes (ytd, volumes are down by 2.6%, 2.9% in Q3), and increased marketing spend (without significant improvement in price mix) have caused negative operational leverage and have driven operating margins down by 1.6% so far this year. According to the company, its cost savings programme has offset inflation, forex and other cost

increases (i.e. more expensive raw materials because the increase in premium brands). Underlying operating profit was down by 13.4% after 9 months. These figures are significantly worse than those published by Labatt with ytd volumes down 0.6% organic (but +7.2% including acquisitions in craft, RTD and cider), net revenue growth of 1.2% organic and an EBIT decline of 2.9% organic. In Europe, year-to-date the benefit of higher net sales and net selling prices per hectoliter in local currency (premiumisation with Coors Light, Staropramen outside of the Czech Republic, and their craft portfolio including Blue Moon, Doom Bar, and other the Sharps brands, as well as Rekorderlig cider), volume and market share in Europe were more than offset by unfavorable foreign currency movements, higher brand amortisation expense, lower pension benefits and the termination of the Heineken contract arrangement in the UK. As a result underlying recorded operating profit for 9 months was down by 14.6% and operating profit margin after 9 months stood at 10.1% v 11.4% 9m 2015.

- However, the **US operations improved**. Overall sales to retail volume decreased 2.5% year-to-date on a trading day adjusted basis driven primarily by value and mainstream light brands, reflecting industry trends (although Coors Light and Miller Lite gained segment market share). However, Coors Banquet and the premium products (including the craft business) increased in volume. Domestic net sales revenue per hectoliter grew 1.2% year-to-date as a result of favorable net pricing and positive sales mix. On the bottom line, U.S. segment underlying equity income increased 9.3% in the 9 months driven primarily by lower cost of goods sold, higher net pricing and positive sales mix.

VALUATION

- DCF based Fair Value of USD112 assuming a risk free rate of 1.7% and a risk premium of 7%. The slight increase from our previous USD110 Fair Value comes on the back of an increased tax advantage from the MillerCoors acquisition (USD275m v USD250m).

NEXT CATALYSTS

- Mid February 2017: 2016 earnings

[Click here to download document](#)



Analyst :
Nikolaas Faes
33(0) 6 11 12 44 44
nfaes@bryangarnier.com

Sector Team :
Loïc Morvan
Antoine Parison
Cédric Rossi
Virginie Roumage

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 72%

NEUTRAL ratings 0%

SELL ratings 28%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			Geneva
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.